Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an increasingly intertwined human-machine model ...

The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to therapy. In a multiomics study of ...

Some proteins embedded in the structure of prions may have antimicrobial activity, according to a study led by scientists at ...

Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract their harmful molecular effects.

An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue. Investors are betting that a deeper ...

In a little more than a month, 17 big biopharma companies will be subject to U.S. President Donald Trump’s long-promised ...

J-Pharma Co. Ltd. is progressing the most clinically advanced L-type amino acid transport 1 (LAT1) inhibitor, nanvuranlat ...

Bionyra Pharma has emerged with a $165 million oversubscribed series A and a portfolio of three antibodies with extended half ...

May was the busiest month of the year so far for U.S. FDA drug approvals, pushing the year-to-date total to 84 approvals and 20 new molecular entities through five months. Globally, drug approvals ...

MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ...

SK Biopharmaceuticals Co. Ltd. is doubling down on AI-powered drug discovery through a new collaboration with Insilico ...